60 F
New York
Friday, May 7, 2021

Akers Biosciences [NASDAQ: AKER] Announces Merger Agreement With MyMD Pharmaceuticals

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Akers Biosciences, Inc. [NASDAQ: AKER] has announced today that it has signed a merger agreement with MyMD Pharmaceuticals, Inc. The merged company will be named MyMD Pharmaceuticals and will continue its listing on NASDAQ but with a new ticker symbol “MYMD”.

The two companies’ motive behind this merger is to focus on developing and commercializing novel immunotherapy pipeline assets of MyMD including MYMD-1. MyMD is also planning to develop its second asset, SUPERA-1R.

MYMD-1 is being developed to treat age-related and autoimmune diseases. Additionally, the company has already executed the Phase I study on MYMD-1. It is also planning to launch two Phase II trials. One in Q1 of 2021 and the second one is throughout 2021.

Shares of Akers Biosciences [NASDAQ: AKER] soared 25.62% as it gained +0.44 during the trading session of Thursday. In the past 52-weeks of trading, this company’s stock has changed between the low of $1.55 and a high of $8.85. It has traded up 39.40% from its 52-weeks low and traded down -75.59% from its 52-weeks high.

Turning our focus on its liquidity, it has a current ratio of 6.80 and a quick ratio of 6.80. Akers Biosciences market capitalization has remained high, hitting $14.62 million at the time of writing.

Akers Biosciences and MyMD Pharmaceuticals are intending to hold a video conference call for investors on November 18, 2020. Furthermore, it has been revealed that the integrated company will be led by Chris Chapman, M.D. He will become President and Chief Medical Officer of MyMD.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...